卡那霉素硫酸盐 | 1966115-71-8

• 物质功能分类: 原料药 - 抗生素类药物 - 氨基糖苷类药
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 卡那霉素硫酸盐
• 中文别名: 硫酸卡那霉素；单硫酸卡那霉素；硫酸卡那辛
• 英文名称: Kanamycin sulfate (1:1) (salt)
• 英文别名: 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol;sulfuric acid
• CAS: 1966115-71-8；70560-51-9
• 化学式: C18H38N4O15S
• 分子量: 582.6
• InChiKey: OOYGSFOGFJDDHP-UHFFFAOYSA-N

物化性质

• 溶解度：
  H2O: 10-50 mg/mL 作为储备液。储备液应储存在 2-8°C。在 37°C 下稳定 5 天。

计算性质

• 辛醇/水分配系数(LogP)：
  -7.94
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  366
• 氢给体数：
  13
• 氢受体数：
  19

制备方法与用途

用途：用于治疗食道炎、胃窦炎、细菌性痢疾以及消化道感染。

文献信息

• CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER
  申请人：(INSERM) Institut National de la Santé et de la Recherche Médicale

  公开号：EP3429597A1

  公开（公告）日：2019-01-23
• [EN] TREATING CANCER USING INHIBITORS OF ATAXIA-TELANGIECTASIA MUTATED AND RAD3-RELATED (ATR)<br/>[FR] TRAITEMENT DU CANCER À L'AIDE D'INHIBITEURS DE L'ATR - ATAXIE-TÉLANGIECTASIE MUTÉE AND RAD3 LIÉE -
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2016112374A9

  公开（公告）日：2017-02-23

  [EN] Methods for identifying and treating cancers, e.g., Alternative Lengthening of Telomeres (ALT)-positive cancers or cancers associated with accumulation of ssDNA, using Ataxia-Telangiectasia mutated and Rad3-related (ATR) inhibitors.
  [FR] L'invention concerne des procédés d'identification et de traitement de cancers, par exemple, de cancers positifs à l'allongement alternatif des télomères ou de cancers liés à l'accumulation de ADN à un seul brin (ssDNA) au moyen d'inhibiteurs de l'ATR - ataxie-télangiectasie mutée et Rad3 liée -.
• [EN] CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER<br/>[FR] INHIBITEURS DE LA CYTIDINE DÉSAMINASE POUR LE TRAITEMENT DU CANCER DU PANCRÉAS
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017158050A1

  公开（公告）日：2017-09-21

  The present invention relates to methods and pharmaceutical compositions for use in the treatment of pancreatic cancer in a subject in need thereof. The inventors showed that targeting cytidine deaminase sensitizes cancer cells to chemotherapy (gemcitabine dFdC) both in vitro and in vivo in experimental models of PDA, with very high efficacy. To their surprise, CDA targeting in the absence of chemotherapy strongly alters cell proliferation and tumor progression. In particular, the present invention relates to a method for treating pancreatic cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a cytidine deaminase inhibitor in combination with an anti-pancreatic cancer treatment selected from the group consisting of CHK1 inhibitor, WEE1 inhibitor, ART inhibitor, DHODH inhibitor or gene therapy.